|

Dexmedetomidine vs Propofol in High-Risk ERCP Patients

RECRUITINGN/ASponsored by Sisli Hamidiye Etfal Training and Research Hospital
Actively Recruiting
PhaseN/A
SponsorSisli Hamidiye Etfal Training and Research Hospital
Started2025-09-03
Est. completion2025-12-30
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

ERCP requires deep sedation due to pain and discomfort, but propofol-commonly used with opioids-often causes respiratory and cardiovascular complications, especially in elderly or high-risk patients. Dexmedetomidine offers sedation without respiratory depression but may lower blood pressure and heart rate. Current monitoring often relies only on SpO₂, while capnography and the Integrated Pulmonary Index (IPI) provide earlier detection of respiratory events but are underused in ERCP studies. This study compares dexmedetomidine and propofol in high-risk ERCP patients, focusing on respiratory and hemodynamic effects, propofol consumption, recovery, and discharge times. The hypothesis is that dexmedetomidine will cause fewer adverse respiratory and hemodynamic effects.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* patients over 18 years of age
* ASA physical status III-IV
* scheduled for ERCP in the Gastroenterology Endoscopy Unit of our hospital

Exclusion Criteria:

* pregnant women;
* patients with neuropsychiatric disease,
* substance abuse, or known allergy to the sedatives used;
* patients with baseline heart rate ≤50 bpm;
* those who did not provide consent.

Conditions6

BradycardiaDepressionHeart DiseaseHypotension Drug-InducedHypoxemiaRespiratory Depression

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.